Ken Griffin Argenx Se Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Argenx Se stock. As of the latest transaction made, Citadel Advisors LLC holds 713,559 shares of ARGX stock, worth $648 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
713,559
Previous 865,970
17.6%
Holding current value
$648 Million
Previous $477 Million
10.26%
% of portfolio
0.09%
Previous 0.09%
Shares
30 transactions
Others Institutions Holding ARGX
# of Institutions
525Shares Held
26MCall Options Held
589KPut Options Held
320K-
Price T Rowe Associates Inc Baltimore, MD3.64MShares$3.31 Billion0.29% of portfolio
-
Janus Henderson Group PLC London, X02.58MShares$2.34 Billion0.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.19MShares$1.99 Billion2.46% of portfolio
-
Capital World Investors Los Angeles, CA1.96MShares$1.78 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY1.01MShares$918 Million0.01% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $50.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...